[1]张国星,李恩泽,温 泉,等.益气养荣汤对结直肠癌术后化疗患者骨髓抑制、Treg/Th17细胞、无进展生存期的影响[J].陕西中医杂志,2024,(4):490-493.[doi:DOI:10.3969/j.issn.1000-7369.2024.04.012]
点击复制

益气养荣汤对结直肠癌术后化疗患者骨髓抑制、Treg/Th17细胞、无进展生存期的影响
分享到：

《陕西中医》杂志[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2024年4期
页码:
490-493
栏目:
临床研究
出版日期:
2024-04-05

文章信息/Info

作者:
张国星1; 李恩泽1; 温 泉1; 王 宇1; 张家维1; 任 壮1; 董玉晶2
(1.齐齐哈尔市中医医院普外科,黑龙江 齐齐哈尔 161005; 2.齐齐哈尔医学院,黑龙江 齐齐哈尔 161006)
关键词:
结直肠癌;  益气养荣汤;  化疗;  骨髓抑制;  无进展生存期;  免疫功能
分类号:
R 735.3
DOI:
DOI:10.3969/j.issn.1000-7369.2024.04.012
文献标志码:
A
摘要:
目的:探讨益气养荣汤对结直肠癌术后化疗患者骨髓抑制、辅助性T细胞17(Th17)/调节性T细胞(Treg)、无进展生存期的影响,以期为临床改善患者生存质量、延长生存期提供参考。方法:选取92例结直肠癌术后患者,随机分为研究组、对照组,各46例。两组患者均行根治手术治疗,对照组术后予以FOLFOX6方案化疗,于此基础上,研究组予以益气养荣汤治疗。比较两组疗效、治疗前后中医症候积分、骨髓抑制程度、外周血细胞水平、免疫指标、生存质量及无进展生存期。结果:研究组总有效率高于对照组(P<0.05)。与治疗前比较,两组治疗1、4个疗程后中医症候主症、次症积分及总积分较低,且研究组低于对照组(均P<0.05)。研究组骨髓抑制发生率低于对照组(P<0.05)。与治疗前比较,两组治疗1、4个疗程后红细胞计数、白细胞计数、血红蛋白、血小板计数较低,但研究组高于对照组(均P<0.05)。相较于治疗前,两组治疗1、4个疗程后Treg细胞、Treg/Th17均显著下降,Th17细胞明显升高,且研究组Treg细胞、Treg/Th17低于对照组,Th17细胞高于对照组(均P<0.05)。与对照组比较,研究组生存质量改善率较高(P<0.05); 研究组1年生存率及无进展生存期高于对照组(均P<0.05)。结论:结直肠癌术后化疗患者联合益气养荣汤治疗效果确切,可促进患者免疫功能改善,减轻骨髓抑制程度及化疗不良反应,改善患者生存质量、延长生存期。

参考文献/References:

[1] BAIDOUN F,ELSHIWY K,ELKERAIE Y,et al.Colorectal cancer epidemiology:Recent trends and impact on outcomes[J].Curr Drug Targets,2021,22(9):998-1009.
[2] YUE T,CHEN S,ZHU J,et al.The aging-related risk signature in colorectal cancer[J].Aging(Albany NY),2021,13(5):7330-7349.
[3] 徐军,白劼.同步放化疗治疗中晚期直肠癌疗效及对肿瘤细胞Bax、Ki-67表达的影响[J].陕西医学杂志,2021,50(5):587-589,602.
[4] DAVIDSON K W,BARRY M J,MANGIONE C M,et al.Screening for colorectal cancer:US preventive services task force recommendation statement[J].JAMA,2021,325(19):1965-1977.
[5] EBRAHIMZADEH S,AHANGARI H,SOLEIMANIAN A,et al.Colorectal cancer treatment using bacteria:Focus on molecular mechanisms[J].BMC Microbiol,2021,21(1):218.
[6] 阿地力江?阿力甫,卡哈尔?吐尔逊,克力比努尔?阿布力米提,等.环丙沙星联合茯苓皮汤加减治疗结直肠癌术后感染临床观察[J].西部中医药,2023,36(4):101-104.
[7] 章玲艳,吴会晨,汪飞,等.参苓白术散加减对结直肠癌患者化疗后骨髓抑制和免疫功能的影响[J].陕西中医,2023,44(8):1086-1089.
[8] 中华人民共和国卫生和计划生育委员会医政医管局,中华医学会肿瘤学分会.中国结直肠癌诊疗规范(2017年版)[J].中华外科杂志,2018,56(4):241-258.
[9] JONES G R,MOLLOY M P.Metformin,microbiome and protection against colorectal cancer[J].Dig Dis Sci,2021,66(5):1409-1414.
[10] PERROD G,RAHMI G,CELLIER C.Colorectal cancer screening in lynch syndrome:Indication,techniques and future perspectives[J].Dig Endosc,2021,33(4):520-528.
[11] WU Q,HUANG Q,JIANG Y,et al.Remodeling chondroitin-6-sulfate-mediated immune exclusion enhances anti-PD-1 response in colorectal cancer with microsatellite stability[J].Cancer Immunol Res,2022,10(2):182-199.
[12] 姚琳,杨帅.硬膜外阻滞联合全身麻醉对老年结直肠癌患者围术期免疫功能及胃肠功能影响的临床研究[J].陕西医学杂志,2022,51(4):449-453.
[13] 汤恒电,王炜.加味六君子汤治疗结直肠癌术后化疗不良反应的临床研究[J].广州中医药大学学报,2023,40(3):596-602.
[14] SUN X,NG T T H,SHAM K W Y,et al.Bufalin,a traditional Chinese medicine compound,prevents tumor formation in two murine models of colorectal cancer[J].Cancer Prev Res(Phila),2019,12(10):653-666.
[15] 李振前,杨梦春,刘戎惠,等.扶正消癌汤合四君子汤联合卡培他滨治疗晚期结直肠癌临床研究[J].陕西中医,2022,43(8):1037-1040.
[16] LIU N,WU C,JIA R,et al.Traditional Chinese medicine combined with chemotherapy and cetuximab or bevacizumab for metastatic colorectal cancer:A randomized,double-blind,placebo-controlled clinical trial[J].Front Pharmacol,2020,21(11):478.
[17] ZHAO H,HE M,ZHANG M,et al.Colorectal cancer,gut microbiota and traditional Chinese medicine:A systematic review[J].Am J Chin Med,2021,49(4):805-828.
[18] LU Y,ZHOU C,ZHU M,et al.Traditional Chinese medicine syndromes classification associates with tumor cell and microenvironment heterogeneity in colorectal cancer:A single cell RNA sequencing analysis[J].Chin Med,2021,16(1):133.
[19] LIU Y T,TZANG B S,YOW J,et al.Traditional Chinese medicine formula T33 inhibits the proliferation of human colorectal cancer cells by inducing autophagy[J].Environ Toxicol,2022,37(5):1007-1017.
[20] 陈益家,唐佳佳,刘世举.八珍散加减改善结直肠癌根治术后患者胃肠功能和免疫功能临床研究[J].陕西中医,2021,42(5):577-581.
[21] BUISMAN F E,FILIPE W F,GALJART B,et al.Adjuvant intra-arterial chemotherapy for patients with resected colorectal liver metastases:A systematic review and meta-analysis[J].HPB(Oxford),2022,24(3):299-308.
[22] RIESCO-MARTINEZ M C,MODREGO A,ESPINOSA-OLARTE P,et al.Perioperative chemotherapy for liver metastasis of colorectal cancer:Lessons learned and future perspectives[J].Curr Treat Options Oncol,2022,23(9):1320-1337.
[23] 王佳媚,杨同堂,孟云,等.健脾益气汤联合FOLFOX化疗治疗梗阻性结直肠癌临床研究[J].新中医,2023,55(2):119-122.
[24] 张远富.用益气健脾汤联合FOLFOX4化疗方案对手术后的结直肠癌患者进行治疗的效果分析[J].当代医药论丛,2022,20(4):169-171.
[25] 汪耔璇,李烜.补中益气汤联合化疗治疗晚期结直肠癌临床研究[J].陕西中医,2020,41(10):1414-1417.

相似文献/References:

[1]吴昭利,李成军,李仁廷,等.通麻汤联合穴位注射治疗结直肠癌奥沙利铂化疗相关外周神经毒性疗效研究*[J].陕西中医杂志,2019,(9):1247.
　WU Zhaoli,LI Chengjun,LI Renting,et al.Clinical study on Tongma decoction combined with acupoint injection in the treatment of peripheral neurotoxicity related to oxaliplatin chemotherapy for colorectal cancer[J].,2019,(4):1247.
[2]林增海,陆 军,王凯松.槲皮素对5-FU诱导的结直肠癌SW480细胞耐药及自噬调控机制研究[J].陕西中医杂志,2021,(10):1338.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.004]
　LIN Zenghai,LU Jun,WANG Kaisong.Regulatory mechanism of quercetin on resistance and autophagy of 5-FU induced colorectal cancer SW480 cells[J].,2021,(4):1338.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.004]
[3]郑佳露,郑金洲,顾 贤.藤龙补中汤联合化疗治疗晚期结直肠癌疗效研究[J].陕西中医杂志,2023,(8):1042.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.010]
　ZHENG Jialu,ZHENG Jinzhou,GU Xian.Observation on the therapeutic effect of Tenglong Buzhong decoction combined with chemotherapy on advanced colorectal cancer[J].,2023,(4):1042.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.010]
[4]章玲艳,吴会晨,汪 飞,等.参苓白术散加减对结直肠癌患者化疗后骨髓抑制和免疫功能的影响[J].陕西中医杂志,2023,(8):1086.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.020]
　ZHANG Lingyan,WU Huichen,WANG Fei,et al.Effects of modified Shenling Baizhu powder on bone marrow suppression and immune function in patients with colorectal cancer after chemotherapy[J].,2023,(4):1086.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.020]

备注/Memo

备注/Memo:
基金项目:黑龙江省自然科学基金资助项目(LH2020H132); 黑龙江省齐齐哈尔市科技计划创新激励项目(CSFGG-2020173)
更新日期/Last Update: 2024-04-10